Merck Pre-Tax Profit Margin 1986-2025 | MRK

Current and historical pre-tax profit margin for Merck (MRK) from 1986 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Merck pre-tax profit margin for the three months ending June 30, 2025 was .
Merck Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2025-06-30 $63.62B $19.16B 30.12%
2025-03-31 $63.92B $20.17B 31.55%
2024-12-31 $64.17B $19.94B 31.07%
2024-09-30 $63.18B $13.72B 21.72%
2024-06-30 $62.48B $15.25B 24.41%
2024-03-31 $61.40B $3.91B 6.37%
2023-12-31 $60.12B $1.89B 3.14%
2023-09-30 $59.31B $7.45B 12.56%
2023-06-30 $58.31B $5.41B 9.28%
2023-03-31 $57.87B $15.23B 26.32%
2022-12-31 $59.28B $16.44B 27.74%
2022-09-30 $58.97B $16.84B 28.55%
2022-06-30 $57.17B $18.52B 32.40%
2022-03-31 $53.98B $15.75B 29.18%
2021-12-31 $48.70B $13.88B 28.50%
2021-09-30 $44.36B $6.55B 14.76%
2021-06-30 $42.14B $3.99B 9.46%
2021-03-31 $40.09B $5.01B 12.50%
2020-12-31 $41.52B $5.86B 14.12%
2020-09-30 $36.49B $7.78B 21.33%
2020-06-30 $37.96B $7.42B 19.56%
2020-03-31 $40.36B $7.94B 19.68%
2019-12-31 $39.12B $7.17B 18.33%
2019-09-30 $45.97B $11.28B 24.53%
2019-06-30 $44.37B $11.60B 26.14%
2019-03-31 $43.07B $10.42B 24.20%
2018-12-31 $42.29B $8.70B 20.57%
2018-09-30 $41.73B $7.98B 19.11%
2018-06-30 $41.26B $5.51B 13.35%
2018-03-31 $40.73B $5.86B 14.40%
2017-12-31 $40.12B $6.52B 16.25%
2017-09-30 $39.80B $3.29B 8.26%
2017-06-30 $40.02B $5.97B 14.93%
2017-03-31 $39.93B $5.04B 12.62%
2016-12-31 $39.81B $4.66B 11.70%
2016-09-30 $39.91B $6.83B 17.12%
2016-06-30 $39.44B $6.34B 16.08%
2016-03-31 $39.39B $5.64B 14.33%
2015-12-31 $39.50B $5.40B 13.67%
2015-09-30 $39.77B $16.40B 41.23%
2015-06-30 $40.25B $15.49B 38.48%
2015-03-31 $41.40B $16.57B 40.03%
2014-12-31 $42.24B $17.28B 40.92%
2014-09-30 $43.08B $6.70B 15.55%
2014-06-30 $43.55B $6.73B 15.46%
2014-03-31 $43.63B $6.09B 13.95%
2013-12-31 $44.03B $5.55B 12.59%
2013-09-30 $44.45B $5.65B 12.72%
2013-06-30 $44.91B $6.35B 14.13%
2013-03-31 $46.21B $7.78B 16.84%
2012-12-31 $47.27B $8.74B 18.49%
2012-09-30 $47.82B $8.99B 18.79%
2012-06-30 $48.36B $9.12B 18.86%
2012-03-31 $48.20B $8.11B 16.83%
2011-12-31 $48.05B $7.33B 15.26%
2011-09-30 $47.85B $5.05B 10.56%
2011-06-30 $46.95B $3.20B 6.81%
2011-03-31 $46.15B $2.77B 5.99%
2010-12-31 $45.99B $1.65B 3.59%
2010-09-30 $43.99B $8.82B 20.05%
2010-06-30 $38.91B $13.40B 34.43%
2010-03-31 $33.47B $14.12B 42.20%
2009-12-31 $27.43B $15.29B 55.75%
2009-09-30 $23.37B $10.78B 46.15%
2009-06-30 $23.26B $7.15B 30.73%
2009-03-31 $23.41B $7.27B 31.06%
2008-12-31 $23.85B $9.93B 41.64%
2008-09-30 $24.06B $4.92B 20.43%
2008-06-30 $24.19B $5.54B 22.89%
2008-03-31 $24.25B $5.68B 23.43%
2007-12-31 $24.20B $3.49B 14.43%
2007-09-30 $24.00B $7.46B 31.10%
2007-06-30 $23.33B $6.63B 28.41%
2007-03-31 $23.00B $6.51B 28.29%
2006-12-31 $22.64B $6.22B 27.48%
2006-09-30 $22.36B $6.83B 30.54%
2006-06-30 $22.36B $7.60B 33.97%
2006-03-31 $22.06B $7.41B 33.60%
2005-12-31 $22.01B $7.36B 33.45%
2005-09-30 $22.03B $7.25B 32.92%
2005-06-30 $22.15B $7.07B 31.91%
2005-03-31 $22.70B $7.58B 33.39%
2004-12-31 $22.97B $8.00B 34.84%
2004-09-30 $22.82B $8.36B 36.62%
2004-06-30 $23.04B $9.15B 39.70%
2004-03-31 $22.55B $9.18B 40.71%
2003-12-31 $22.49B $9.05B 40.26%
2003-09-30 $7.90B $9.61B 121.66%
2003-06-30 $7.56B $9.52B 125.81%
2003-03-31 $14.85B $9.55B 64.29%
2002-12-31 $21.45B $9.65B 45.01%
2002-09-30 $16.45B $9.54B 57.99%
2002-06-30 $22.94B $9.81B 42.76%
2002-03-31 $22.02B $9.90B 44.97%
2001-12-31 $21.20B $9.95B 46.93%
2001-09-30 $46.63B $10.26B 22.00%
2001-06-30 $45.27B $10.12B 22.34%
2001-03-31 $42.86B $10.00B 23.33%
2000-12-31 $40.36B $9.82B 24.34%
2000-09-30 $37.86B $9.52B 25.16%
2000-06-30 $35.49B $9.12B 25.69%
2000-03-31 $34.03B $8.97B 26.36%
1999-12-31 $32.71B $8.62B 26.35%
1999-09-30 $31.28B $8.37B 26.74%
1999-06-30 $29.92B $8.85B 29.56%
1999-03-31 $28.38B $8.34B 29.39%
1998-12-31 $26.90B $8.13B 30.24%
1998-09-30 $25.60B $7.85B 30.66%
1998-06-30 $24.69B $6.83B 27.66%
1998-03-31 $24.13B $6.63B 27.50%
1997-12-31 $23.64B $6.46B 27.34%
1997-09-30 $22.81B $6.26B 27.44%
1997-06-30 $21.87B $6.00B 27.45%
1997-03-31 $20.87B $5.76B 27.62%
1996-12-31 $19.83B $5.54B 27.94%
1996-09-30 $18.98B $5.28B 27.84%
1996-06-30 $18.17B $5.09B 28.03%
1996-03-31 $17.39B $4.94B 28.41%
1995-12-31 $16.68B $4.80B 28.76%
1995-09-30 $16.00B $4.67B 29.20%
1995-06-30 $15.62B $4.60B 29.43%
1995-03-31 $15.27B $4.50B 29.46%
1994-12-31 $14.97B $4.42B 29.50%
1994-09-30 $14.10B $4.29B 30.43%
1994-06-30 $12.85B $4.12B 32.09%
1994-03-31 $11.63B $3.20B 27.52%
1993-12-31 $10.50B $3.10B 29.55%
1993-09-30 $10.10B $2.97B 29.44%
1993-06-30 $10.02B $2.89B 28.89%
1993-03-31 $9.82B $3.62B 36.87%
1992-12-31 $9.66B $3.56B 36.89%
1992-09-30 $9.38B $3.52B 37.59%
1992-06-30 $9.03B $3.41B 37.74%
1992-03-31 $8.78B $3.28B 37.42%
1991-12-31 $8.60B $3.17B 36.82%
1991-09-30 $8.39B $3.04B 36.23%
1991-06-30 $8.19B $2.92B 35.68%
1991-03-31 $7.96B $2.81B 35.33%
1990-12-31 $7.67B $2.70B 35.18%
1990-09-30 $7.33B $2.59B 35.37%
1990-06-30 $7.05B $2.49B 35.37%
1990-03-31 $6.74B $2.38B 35.34%
1989-12-31 $6.55B $2.28B 34.85%
1989-09-30 $6.32B $2.20B 34.83%
1989-06-30 $6.16B $2.09B 33.98%
1989-03-31 $6.07B $1.98B 32.55%
1988-12-31 $5.94B $1.87B 31.48%
1988-09-30 $5.80B $1.75B 30.24%
1988-06-30 $5.64B $1.64B 29.07%
1988-03-31 $5.39B $1.51B 28.10%
1987-12-31 $5.06B $1.41B 27.76%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $270.018B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12